Stock APRE APREA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Aprea Therapeutics, Inc.

Equities

APRE

US03836J2015

Market Closed - Nasdaq
Other stock markets
 02:00:00 03/05/2024 am IST 		5-day change 1st Jan Change
5.45 USD +3.81% Intraday chart for Aprea Therapeutics, Inc. +1.87% +15.96%
03:15pm Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza as Chief Medical Officer CI
10/04 Aprea Therapeutics, Inc. Announces Presentations on Its Next Generation Wee1 Inhibitor, Apr-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, At AACR Annual Meeting 2024 CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer and Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
AQ
Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024
AQ
Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
AQ
Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million
AQ
Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers
AQ
Aprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024
AQ
Aprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase Inhibitor
AQ
Aprea Therapeutics to Present at DDR Inhibitors Summit 2024
AQ
Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024
AQ
Aprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
AQ
Aprea Therapeutics to Host a Key Opinion Leader (KOL) Event on its Synthetic Lethality (SL) and DNA Damage Response (DDR) Pathways
AQ
Aprea Unveils Initial Clinical Data on ATRi, ATRN-119, and Pre-Clinical Data on WEE1i, ATRN-1051, at AACR-NCI-EORTC International Conference Supporting Highly Differentiated Synthetic Lethality Portfolio
AQ
Aprea Therapeutics Announces Two Posters at the Upcoming 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
AQ
Aprea Announces Preclinical Data Supporting Highly Differentiated WEE1 Inhibitor, ATRN-1051, Relative To Other WEE1 Inhibitors
AQ
Aprea Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
AQ
Aprea Therapeutics Appoints Dr. Jean-Pierre Bizzari to its Board of Directors and Names Dr. Richard Peters as Chairman
AQ
Aprea Therapeutics Reports Second Quarter 2023 Financial Results and Provides Update on Business Operations
AQ
Aprea Therapeutics to Present at Maxim Virtual Healthcare Conference
AQ
Aprea Therapeutics to Present at BIO International Convention
AQ
APREA THERAPEUTICS, INC. : Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. APRE Stock
  4. News Aprea Therapeutics, Inc.
  5. Press Releases